Skip to main content
IN8BIO, INC. logo

IN8BIO, INC. — Investor Relations & Filings

Ticker · INAB ISIN · US45674E1091 LEI · 549300H68IVCRKSGSL94 US Manufacturing
Filings indexed 380 across all filing types
Latest filing 2026-05-18 Registration Form
Country US United States of America
Listing US INAB

About IN8BIO, INC.

https://www.in8bio.com

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Recent filings

Filing Released Lang Actions
S-3/A
Registration Form
2026-05-18 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings
2026-05-07 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings
2026-05-07 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings
2026-05-07 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings
2026-05-07 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings
2026-05-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.